August 2023 – Eternygen published new data: citrate transporter INDY/NaCT/SLC13A5 as a therapeutic target for kidney diseases

In collaboration with Dipender Gill and Stephen Burgess, we’ve identified a noteworthy new connection between hepatic INDY/SLC13A5 and kidney function. This finding underscores the therapeutic potential of our small molecule inhibitor in addressing kidney diseases.

Find more information here.